79 related articles for article (PubMed ID: 23928732)
1. Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo.
Xu CM; Liu WW; Liu CJ; Wen C; Lu HF; Wan FS
Cancer Gene Ther; 2013 Aug; 20(8):453-60. PubMed ID: 23928732
[TBL] [Abstract][Full Text] [Related]
2. The Hippo kinases control inflammatory Hippo signaling and restrict bacterial infection in phagocytes.
St Louis BM; Quagliato SM; Su Y-T; Dyson G; Lee P-C
mBio; 2024 May; 15(5):e0342923. PubMed ID: 38624208
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new class of activators of the Hippo pathway with antitumor activity in vitro and in vivo.
Lin G; Xia A; Qiao J; Zhang H; Chen P; Zhou P; Hu Q; Xiang Z; Zhang S; Li L; Yang S
Biochem Pharmacol; 2024 Jun; 224():116217. PubMed ID: 38641306
[TBL] [Abstract][Full Text] [Related]
4. The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation.
Dong A; Gupta A; Pai RK; Tun M; Lowe AW
J Biol Chem; 2011 May; 286(20):18301-10. PubMed ID: 21454516
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the Hippo signalling pathway.
Hwang E; Cheong HK; Ul Mushtaq A; Kim HY; Yeo KJ; Kim E; Lee WC; Hwang KY; Cheong C; Jeon YH
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1944-53. PubMed ID: 25004971
[TBL] [Abstract][Full Text] [Related]
6. MST1/MST2 Protein Kinases: Regulation and Physiologic Roles.
Galan JA; Avruch J
Biochemistry; 2016 Oct; 55(39):5507-5519. PubMed ID: 27618557
[TBL] [Abstract][Full Text] [Related]
7. MST1/2: Important regulators of Hippo pathway in immune system associated diseases.
Zhou J; Li L; Wu B; Feng Z; Lu Y; Wang Z
Cancer Lett; 2024 Apr; 587():216736. PubMed ID: 38369002
[TBL] [Abstract][Full Text] [Related]
8. Characterization of two Mst1-deficient mouse models.
Anguera MC; Liu M; Avruch J; Lee JT
Dev Dyn; 2008 Nov; 237(11):3424-34. PubMed ID: 18942145
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.
Davidson K; Grevitt P; Contreras-Gerenas MF; Bridge KS; Hermida M; Shah KM; Mardakheh FK; Stubbs M; Burke R; Casado P; Cutillas PR; Martin SA; Sharp TV
Cell Death Dis; 2021 Nov; 12(11):1075. PubMed ID: 34764236
[TBL] [Abstract][Full Text] [Related]
10. HAX1-Overexpression Augments Cardioprotective Efficacy of Stem Cell-Based Therapy Through Mediating Hippo-Yap Signaling.
Cai WF; Jiang L; Liang J; Dutta S; Huang W; He X; Wu Z; Paul C; Gao X; Xu M; Kanisicak O; Zheng J; Wang Y
Stem Cell Rev Rep; 2024 May; ():. PubMed ID: 38713406
[TBL] [Abstract][Full Text] [Related]
11. A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis.
Watkins R; Gamo A; Choi SH; Kumar M; Buckarma E; McCabe C; Tomlinson J; Pereya D; Lupse B; Geravandi S; Werneburg NW; Wang C; Starlinger P; Zhu S; Li S; Yu S; Surakattula M; Baguley T; Ardestani A; Maedler K; Roland J; Nguyen-Tran V; Joseph S; Petrassi M; Rogers N; Gores G; Chatterjee A; Tremblay M; Shen W; Smoot R
PNAS Nexus; 2024 Mar; 3(3):pgae096. PubMed ID: 38528952
[TBL] [Abstract][Full Text] [Related]
12. Hippo pathway regulation of gastrointestinal tissues.
Yu FX; Meng Z; Plouffe SW; Guan KL
Annu Rev Physiol; 2015; 77():201-27. PubMed ID: 25293527
[TBL] [Abstract][Full Text] [Related]
13. CD44 acts through RhoA to regulate YAP signaling.
Zhang Y; Xia H; Ge X; Chen Q; Yuan D; Chen Q; Leng W; Chen L; Tang Q; Bi F
Cell Signal; 2014 Nov; 26(11):2504-13. PubMed ID: 25101858
[TBL] [Abstract][Full Text] [Related]
14. Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway.
Chao Y; Wang Y; Liu X; Ma P; Shi Y; Gao J; Shi Q; Hu J; Yu R; Zhou X
J Neurooncol; 2015 Jan; 121(2):279-88. PubMed ID: 25373346
[TBL] [Abstract][Full Text] [Related]
15. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P; Mottolese M; Pizzuti L; Barba M; Sperati F; Terrenato I; Di Benedetto A; Natoli C; Gamucci T; Angelucci D; Ramieri MT; Di Lauro L; Sergi D; Bartucci M; Dattilo R; Pagliuca A; De Maria R; Maugeri-Saccà M
Oncotarget; 2014 Oct; 5(20):9619-25. PubMed ID: 25294813
[TBL] [Abstract][Full Text] [Related]
16. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
Kodaka M; Hata Y
Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
[TBL] [Abstract][Full Text] [Related]
17. One Hippo and many masters: differential regulation of the Hippo pathway in cancer.
Romano D; Matallanas D; Frederick DT; Flaherty KT; Kolch W
Biochem Soc Trans; 2014 Aug; 42(4):816-21. PubMed ID: 25109963
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rh2 attenuates the progression of non-small cell lung cancer by sponging miR-28-5p/STK4 axis and inactivating Wnt/β-catenin signaling.
Ma J; Zhao D; Yu D; Song W; Yang X; Yin H
Cancer Med; 2023 Jun; 12(11):12653-12667. PubMed ID: 37081781
[TBL] [Abstract][Full Text] [Related]
19. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
[TBL] [Abstract][Full Text] [Related]
20. The Role of Nonapoptotic Programmed Cell Death - Ferroptosis, Necroptosis, and Pyroptosis - in Pancreatic Ductal Adenocarcinoma Treatment.
Hsu SK; Chu YH; Syue WJ; Lin HY; Chang WT; Chen JY; Wu CY; Yen CH; Cheng KC; Chiu CC
Front Oncol; 2022; 12():872883. PubMed ID: 35664778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
